NCT03695094View on ClinicalTrials.gov

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

May 18, 2019

Study Completion Date

May 30, 2019

Conditions
Epilepsy
Interventions
DRUG

Padsevonil

Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed

DRUG

Oxcarbazepine

Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage

DRUG

Levetiracetam

Concomitant administration of levetiracetam (LEV) at therapeutic dosage

DRUG

Lamotrigine

Concomitant administration of lamotrigine (LTG) at therapeutic dosage

DRUG

Brivaracetam

Concomitant administration of brivaracetam (BRV) at therapeutic dosage

Trial Locations (2)

Unknown

Up0070 101, Sofia

Up0070 401, Leiden

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT03695094 - A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil | Biotech Hunter | Biotech Hunter